Optimization of an HCN1-selective inverse agonist for the treatment of peripheral neuropathic pain
Ended Project Grant Awarded Last action
- Award ID
- R42NS129370
- Recipient
-
Akelos Inc. UEI JLTKFBSDPLR4
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,747,045
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Originally
- Place of performance
- New York, NY 10065, USA
Award details come from USAspending.gov.
Description
- Abstract
- In the united states, at least 116 million adults suffer from chronic pain; the associated costs exceed $500 billion/YR. Neuropathic pain (chronic pain associated with aberrant activity in the central and/or peripheral nervous system) accounts for 18% of patients with chronic pain. Opioid analgesics are routinely prescribed for the treatment of chronic pain but there are substantial risks involved with such therapy, including physical dependence, addiction, and fatal poisoning. The goals of this project are to optimize the active pharmacophore component of our identified lead compound and use that novel molecule to create a potent, non-opioid therapeutic for the treatment of peripheral sensory neuropathic pain. IH current-driven hyperexcitability in sensory neurons contributes to neuropathic pain. We have previously demonstrated that the widely used and safe general anesthetic propofol (2,6-DI-ISO-propylphenol), as well as closely related analogues, are potent HCN1 inverse agonists (i.e., they act as inhibitors of channel function), markedly sparing other HCN isoforms including those that form cardiac IH (HCN4 and 2). Importantly, sub- hypnotic propofol and the non-anesthetic 2,6-DI-tert-butylphenol (2,6-dtbp) suppress neuropathic hyperalgesia while largely sparing normal nociception. Here we will screen in vitro a compound library constrained by known inverse agonist-site characteristics of alkylphenol congeners to identify novel potent, selective HCN1 channel inverse agonists; use in silico modeling to predict and then synthesize additional novel, potent, HCN1-selective molecules; and conduct in vivo studies using the two most potent of those novel compounds to assess anti-hyperalgesic efficacy and safety. Successful completion of the proposed work will create an urgently needed, highly-effective, non-opioid, treatment for neuropathic pain.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $349,409 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $349,409 | |
| Amendment | $349,409 | |
| Amendment | $349,409 | |
| Original award | $349,409 |
Show all 13
Quick answers
Who received award R42NS129370?
R42NS129370 was awarded to Akelos Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 23, 2022.
How much is award R42NS129370 worth?
$1,747,045 has been obligated on R42NS129370.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award